Mustang Bio (MBIO) Change in Accured Expenses (2016 - 2019)
Mustang Bio (MBIO) posted quarterly Change in Accured Expenses of $76000.0 for Q3 2019, down 92.26% year-over-year from $982000.0 in Q3 2018, and up 105.8% quarter-over-quarter from -$1.3 million in Q2 2019.
Mustang Bio (MBIO) Change in Accured Expenses (2016 - 2019) Analysis & Trends
Mustang Bio (MBIO) has reported Change in Accured Expenses for 4 consecutive years, with $76000.0 the latest figure, recorded in Q3 2019.
- In Q3 2019, Change in Accured Expenses fell 92.26% year-over-year to $76000.0; the TTM figure through Sep 2019 stood at $1.1 million (up 106.96% YoY), while the FY2018 annual figure was $2.5 million, up 85.44% from the prior year.
- Change in Accured Expenses advanced to $76000.0 in Q3 2019 per MBIO's latest filing, from -$1.3 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $2.7 million in Q2 2017 and bottomed at -$1.3 million in Q2 2019.
- Historically, Change in Accured Expenses has averaged $284466.7 across 4 years, with a median of $93000.0 in 2016.
- On a YoY basis, Change in Accured Expenses climbed as much as 2809.68% in 2017 and fell as far as 607.41% in 2017.
- Mustang Bio's Change in Accured Expenses stood at $390000.0 in 2016, then slumped by 251.54% to -$591000.0 in 2017, then soared by 325.55% to $1.3 million in 2018, then plunged by 94.3% to $76000.0 in 2019.
- Business Quant data shows MBIO's Change in Accured Expenses at $76000.0 in Q3 2019, -$1.3 million in Q2 2019, and $1.0 million in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Mustang Bio | 3.90 Mn | 3.90 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 76,000.00 |
| Sep 30, 2019 | 76,000.00 |
| Jun 30, 2019 | -1.31 Mn |
| Jun 30, 2019 | -1.31 Mn |
| Mar 31, 2019 | 1.03 Mn |
| Mar 31, 2019 | 1.03 Mn |
| Dec 31, 2018 | 1.33 Mn |
| Dec 31, 2018 | 1.33 Mn |
| Sep 30, 2018 | 982,000.00 |
| Sep 30, 2018 | 982,000.00 |
| Jun 30, 2018 | 942,000.00 |
| Jun 30, 2018 | 942,000.00 |
| Mar 31, 2018 | -787,000.00 |
| Mar 31, 2018 | -787,000.00 |
| Dec 31, 2017 | -591,000.00 |
| Dec 31, 2017 | -591,000.00 |
| Sep 30, 2017 | -372,000.00 |
| Sep 30, 2017 | -372,000.00 |
| Jun 30, 2017 | 2.71 Mn |
| Jun 30, 2017 | 2.71 Mn |